Research Triangle Park, NC — (Marketwired) – June 7, 2018– Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 30, 2018 (the “Circular”) for the Annual General and Special Meeting of Shareholders were elected as directors of the Company at the Annual General and […]
Category: Press Releases
Fennec Provides Business Update and Announces First Quarter 2018 Financial Results
PEDMARK TM granted Breakthrough Therapy and Fast Track Designations by FDA Actively preparing for NDA submission later this year Strong financial position with $26.7 million in cash and no debt RESEARCH TRIANGLE PARK, N.C., May 14, 2018 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARK TM (a […]
Read More… from Fennec Provides Business Update and Announces First Quarter 2018 Financial Results
FENNEC PHARMACEUTICALS RECEIVES BREAKTHROUGH THERAPY DESIGNATION BY FDA FOR PEDMARK™
Research Triangle Park, NC, March 27, 2018 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted PEDMARK™ (a unique formulation of sodium thiosulfate) Breakthrough Therapy designation for prevention of cisplatin-related ototoxicity in pediatric patients with standard risk hepatoblastoma (SR-HB). “The decision […]
Read More… from FENNEC PHARMACEUTICALS RECEIVES BREAKTHROUGH THERAPY DESIGNATION BY FDA FOR PEDMARK™
FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES FISCAL YEAR ENDED DECEMBER 31, 2017 FINANCIAL RESULTS
Phase 3 SIOPEL 6 study met primary endpoint (p=0.0033) NASDAQ listing in September 2017 Two equity financings completed Strong financial position at year end with $28.3 million in cash and no debt Research Triangle Park, NC, March 26, 2018 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of […]
FENNEC PHARMACEUTICALS RECEIVES FAST TRACK DESIGNATION BY FDA FOR PEDMARK
Research Triangle Park, NC, March 21, 2018 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted PEDMARK (a unique formulation of sodium thiosulfate) Fast Track designation for prevention of cisplatin-related ototoxicity in pediatric patients with standard risk hepatoblastoma (SR-HB). There are […]
Read More… from FENNEC PHARMACEUTICALS RECEIVES FAST TRACK DESIGNATION BY FDA FOR PEDMARK
Fennec Announces Closing of Public Offering
Research Triangle Park, N.C., December 12, 2017 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a biotechnology company focused on the development of PEDMARK TM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity from cisplatin in pediatric cancer patients, today announced the closing of its previously announced underwritten public offering of 2,352,950 […]
Fennec Announces Pricing of Public Offering
RESEARCH TRIANGLE PARK, N.C., Dec. 08, 2017 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a biotechnology company focused on the development of PEDMARK TM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity from cisplatin in pediatric cancer patients, today announced the pricing of its underwritten public offering of 2,352,950 common […]
Fennec Announces Proposed Public Offering of Common Shares
RESEARCH TRIANGLE PARK, N.C., Dec. 07, 2017 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a biotechnology company focused on the development of PEDMARK™ (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity from cisplatin in pediatric cancer patients, today announced that it intends to offer its common shares in an underwritten […]
Read More… from Fennec Announces Proposed Public Offering of Common Shares
Fennec Provides Business Update And Reports Third Quarter 2017 Results
During the third quarter, the Company announced positive results from its Phase 3 SIOPEL 6 Study Study met primary endpoint (p=0.0033) indicating a significant reduction in cisplatin induced hearing loss without any evidence of tumor protection in patients with Standard Risk Hepatoblastoma (SR-HB) Company plans to pursue regulatory approvals with FDA and EU in 2018 […]
Read More… from Fennec Provides Business Update And Reports Third Quarter 2017 Results
Fennec Announces Positive Results From Phase 3 SIOPEL 6 Study on PEDMARK™ (sodium thiosulfate) Presented at the 49th Congress of the International Society of Pediatric Oncology (SIOP) 2017 Meeting
Study met primary endpoint (p=0.0033) Significant reduction in cisplatin induced hearing loss without any evidence of tumour protection in patients with Standard Risk Hepatoblastoma (SR-HB) Company plans to pursue regulatory approvals with FDA and EMA RESEARCH TRIANGLE PARK, N.C., Oct. 16, 2017 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused […]